List of Excipients in Branded Drug APOKYN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
MDD US Operations LLC	APOKYN	apomorphine hydrochloride	27505-004	BENZYL ALCOHOL
MDD US Operations LLC	APOKYN	apomorphine hydrochloride	27505-004	HYDROCHLORIC ACID
MDD US Operations LLC	APOKYN	apomorphine hydrochloride	27505-004	SODIUM HYDROXIDE
MDD US Operations LLC	APOKYN	apomorphine hydrochloride	27505-004	SODIUM METABISULFITE
MDD US Operations LLC	APOKYN	apomorphine hydrochloride	27505-004	WATER

APOKYN Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

APOKYN is a subcutaneous apomorphine hydrochloride injection used for acute, intermittent treatment of “off” episodes in patients with Parkinson’s disease. Its commercial formulation is relatively simple: an acidic aqueous solution containing apomorphine hydrochloride, sodium chloride, citrate buffers, sodium metabisulfite, and water for injection. The principal excipient opportunity is not cost reduction. It is the development of a more stable, sulfite-free, device-compatible formulation that reduces administration friction and expands use outside the current multidose vial format. [1]

The strongest commercial opportunities are:

1. Sulfite-free or sulfite-reduced apomorphine formulations.
2. Prefilled syringes, cartridges, and autoinjectors.
3. Improved stability against oxidation and light exposure.
4. Lower-volume, higher-concentration presentations.
5. Excipient-device combinations that support 505(b)(2) or differentiated generic strategies.
6. Reformulations that reduce preparation steps, dosing errors, and injection-site burden.

What excipients are used in APOKYN?

APOKYN is an acidic, sterile injectable formulation. The FDA prescribing information identifies the inactive ingredients as sodium chloride, sodium citrate dihydrate, citric acid monohydrate, sodium metabisulfite, and water for injection. The product is supplied as a 10 mg/mL solution for subcutaneous administration. [1]

Component	Function	Commercial relevance
Sodium metabisulfite	Antioxidant	Controls oxidative degradation of apomorphine; creates sulfite-sensitivity and labeling considerations
Citric acid monohydrate	Acidifying agent and buffer component	Helps maintain the acidic formulation environment
Sodium citrate dihydrate	Buffer component	Supports pH control during storage
Sodium chloride	Tonicity adjustment	Supports physiologic compatibility
Water for injection	Vehicle	Sterile aqueous carrier
Apomorphine hydrochloride	Active pharmaceutical ingredient	Oxidation-sensitive dopamine agonist

The formulation is administered subcutaneously through a dedicated injection system or syringe-based procedure. Patients may require dose titration and antiemetic management, which increases the importance of ease of use and reliable dose delivery. [1]

Why is sulfite important in apomorphine injection?

Sodium metabisulfite is strategically important because apomorphine is susceptible to oxidative degradation. The antioxidant helps preserve assay, impurity profile, color, and shelf life in an aqueous injection.

The same excipient creates a product-development constraint. Sulfites can cause hypersensitivity reactions in susceptible patients, particularly those with asthma. APOKYN labeling includes a warning regarding sulfite sensitivity. [1] A sulfite-free formulation could therefore support a differentiated product if it maintains stability through the full labeled shelf life and normal in-use conditions.

A sulfite-free product would need to address:

• Oxidation of apomorphine and formation of degradation products.
• Protection from oxygen in the vial, syringe, or cartridge headspace.
• Light sensitivity during manufacturing, storage, and administration.
• Compatibility with elastomeric closures, needle shields, and device lubricants.
• Container closure integrity.
• Extractables and leachables.
• Stability after repeated vial punctures or partial-dose withdrawal.

Potential antioxidant alternatives include ascorbate systems, chelating agents, amino-acid-based stabilizers, and oxygen-control approaches. These are not interchangeable. An alternative must be evaluated for pH impact, injectable safety, metal-ion interactions, color formation, compatibility with the primary container, and regulatory precedent.

What formulation patents could protect APOKYN alternatives?

The most defensible intellectual-property position would likely come from a combination of formulation and delivery claims rather than from a broad claim to apomorphine itself.

Potential claim categories include:

Sulfite-free compositions

Claims could cover apomorphine hydrochloride in an aqueous solution that excludes sulfite while maintaining specified pH, impurity limits, and stability thresholds. The value of such claims would depend on whether the formulation uses a specific antioxidant, chelator, buffer ratio, oxygen-control method, or container configuration.

Concentrated formulations

A higher-concentration product could reduce injection volume and support a prefilled pen or autoinjector. Claims may focus on:

• Apomorphine concentration.
• Buffer identity and concentration.
• Osmolality.
• pH range.
• Maximum impurity level.
• Stability after temperature excursions.
• Compatibility with a specific delivery device.

Device-compatible formulations

A formulation may be patentable in combination with a cartridge, pen, syringe, or autoinjector if the combination solves a defined technical problem. Relevant limitations could include viscosity, delivered volume, needle gauge, dose accuracy, hold time, and residual volume.

In-use stability

The marketed product and its administration method create opportunities for claims covering stability after vial puncture, repeated withdrawals, exposure to ambient light, or use over a defined period after opening.

Manufacturing processes

Process claims may address oxygen control, nitrogen purging, low-light compounding, sterilizing filtration, aseptic filling, or control of metal contaminants. These claims can create practical barriers even when composition claims are narrow.

A formulation patent would be strongest when supported by comparative data against the existing sulfite-containing formulation. Evidence should show improved tolerability or usability without sacrificing chemical stability, sterility, dose accuracy, or shelf life.

When does APOKYN lose exclusivity?

APOKYN received FDA approval in the United States in 2004. Regulatory exclusivity from the original approval has expired. Commercial protection therefore depends primarily on patents, trademarks, formulation claims, device rights, manufacturing know-how, and market access rather than on the original new-drug exclusivity period. [2]

The relevant FDA pathway for a competing product depends on the proposed presentation:

Product strategy	Likely regulatory route	Main barrier
Same apomorphine injection, same route and strength	ANDA	Pharmaceutical equivalence, bioequivalence or waiver, device and labeling requirements
Reformulated sulfite-free injection	505(b)(2) or ANDA, depending on sameness	Stability, excipient justification, clinical or bridging data
New pen or autoinjector	505(b)(2), combination-product pathway, or device-linked application	Human factors, dose accuracy, usability, container closure
New indication or dosing regimen	505(b)(2) or supplemental application	Clinical evidence and method-of-use protection
Apomorphine product outside the United States	National or regional pathway	Local excipient, device, and patent requirements

The Orange Book should be used to identify current listed patents and pediatric exclusivity, if any. Patent expiration dates must be assessed patent by patent because composition, method-of-use, formulation, and device-related rights can expire on different dates. [2] A commercial assessment should not treat the 2004 approval date as the end of all potential market protection.

What is the Orange Book status of APOKYN?

APOKYN is an FDA-listed prescription drug product. Orange Book analysis should separate:

1. The active ingredient and dosage form.
2. Any listed patents.
3. Patent expiration dates.
4. Use codes for method-of-use patents.
5. Paragraph IV certification exposure.
6. Whether an applicant can carve out protected indications.
7. Whether a listed patent covers the formulation, device, or use rather than the active ingredient.

A generic apomorphine injection could face different risks depending on whether the reference product’s listed rights cover the same formulation or only a particular use. A label carve-out may reduce method-of-use exposure but would not avoid composition or formulation claims.

Which companies could challenge APOKYN?

The likely challenger groups are generic injectable manufacturers, specialty pharmaceutical companies, and drug-device developers with experience in Parkinson’s disease or rescue therapies.

Potential entrants would prioritize:

• Apomorphine hydrochloride injection manufacturers.
• Sterile injectable companies with small-volume parenteral capacity.
• Firms with cartridge and autoinjector platforms.
• Specialty companies seeking a lower-cost Parkinson’s rescue product.
• Developers using 505(b)(2) strategies to improve administration.

The commercial market is not equivalent to a conventional high-volume generic opportunity. APOKYN requires specialty distribution, patient titration, training, and Parkinson’s-focused prescriber access. A challenger may therefore compete through a differentiated device or service model rather than through price alone.

What Paragraph IV risks exist for APOKYN?

A Paragraph IV challenge could target an Orange Book-listed patent by asserting that the patent is invalid, unenforceable, or not infringed. The main risk categories are:

Formulation patent challenge

A generic applicant could argue that the proposed excipient system does not meet the asserted claim limitations. A narrow patent covering a specific antioxidant combination or pH range may be easier to design around than a broader claim covering any stabilized apomorphine injection.

Method-of-use challenge

A proposed label may omit a protected use. This strategy depends on the scope of the use code and whether the remaining label still encourages the patented use.

Device patent challenge

A device claim may be less relevant to a conventional vial-and-syringe generic, but it could become important for a pen, cartridge, or autoinjector competitor.

Manufacturing patent challenge

Manufacturing claims may be difficult to detect from the finished product. They can create litigation exposure if the applicant uses a process that falls within the patent claims.

For a small specialty product, litigation economics can materially affect launch timing. A 30-month stay, preliminary injunction, settlement, or supply agreement may be more significant than the underlying patent term if the market has limited annual volume.

What excipient strategy could create a better APOKYN product?

1. Sulfite-free oxidation control

This is the clearest formulation opportunity. A successful alternative would preserve apomorphine stability while removing the sulfite warning from the product profile. The development program should compare:

• Sulfite-containing control.
• Sulfite-free antioxidant system.
• Chelator-containing system.
• Oxygen-reduced packaging.
• Light-protective packaging.
• Different citrate buffer concentrations.
• Different pH targets within the clinically acceptable range.

The key commercial endpoint is not merely chemical stability. It is a label and usability profile that supports meaningful differentiation.

2. Prefilled syringe

A prefilled syringe could reduce vial punctures, preparation steps, and dosing errors. It could also reduce residual drug loss. The principal excipient issues are syringe-material compatibility, silicone oil, tungsten residues, needle-shield compatibility, and extractables.

3. Autoinjector or pen

A pen could improve dose titration and administration for patients with motor impairment. A higher concentration would reduce delivered volume, but concentration increases may affect precipitation, viscosity, local tolerability, and dose accuracy.

4. Oxygen-managed packaging

A formulation using low-oxygen headspace, nitrogen overlay, oxygen-scavenging secondary packaging, or a specialized container closure could improve stability without changing the excipient system substantially. This approach may be easier to develop than a completely new antioxidant system, although the patent position may be narrower.

5. Reduced injection-site burden

A reformulation could target lower injection volume, less irritation, or fewer injections. Buffer strength, osmolality, pH, concentration, and excipient load all affect local tolerability. Any claim of improved tolerability would require comparative clinical or human-use evidence.

How does APOKYN compare with competing Parkinson’s rescue products?

APOKYN competes with other approaches to treating motor fluctuations, including inhaled levodopa and subcutaneous foslevodopa/foscarbidopa systems. These products differ in active ingredient, route, onset profile, device burden, and formulation complexity.

Product type	Route	Excipient opportunity	Commercial advantage
APOKYN	Subcutaneous apomorphine	Antioxidant replacement, concentration, device	Established rescue use and known pharmacology
Inhaled levodopa	Pulmonary	Particle engineering and inhalation excipients	Avoids injection
Continuous subcutaneous levodopa systems	Subcutaneous infusion	Long-term infusion stability and device compatibility	Continuous delivery
Oral rescue therapies	Oral	Absorption enhancers and release control	Lower administration burden

APOKYN’s excipient opportunity is strongest where the product can retain rapid rescue performance while reducing injection complexity. A device-only improvement may be easier to commercialize than a new chemical formulation, but it may produce weaker patent protection and more direct competition.

What FDA regulatory issues affect a reformulated APOKYN product?

The FDA will evaluate the total product, including formulation, container closure, delivery device, labeling, and manufacturing process. Key requirements include:

• Assay and degradation-product specifications.
• Sterility and bacterial endotoxin controls.
• Particulate matter.
• Subvisible particles.
• Extractables and leachables.
• Container closure integrity.
• In-use stability.
• Dose delivery accuracy.
• Device usability and human factors.
• Compatibility with the proposed administration method.
• Justification for each new excipient and concentration.

A 505(b)(2) application may be commercially attractive for a differentiated formulation or device because it can rely in part on FDA findings for the reference drug. The applicant would still need to support the differences between the reference product and the proposed product. [3]

What manufacturing and intellectual-property barriers exist?

The main manufacturing barrier is maintaining apomorphine quality during compounding, filling, sterilization-related processing, storage, and administration. Oxidation control must be embedded into the full process rather than treated as a single-excipient issue.

Important technical controls include:

• Low-metal-contact processing equipment.
• Controlled oxygen exposure.
• Light-protected compounding and filling.
• Validated sterilizing filtration.
• Low-oxygen headspace.
• Compatible elastomers and syringe materials.
• Tight control of pH and buffer composition.
• Stability testing under shipping and in-use conditions.

A competitor may be able to avoid a composition patent yet remain exposed to process or device patents. Conversely, a technically superior formulation may have limited commercial value if it requires expensive specialty manufacturing or a new administration system that patients are reluctant to adopt.

What licensing deals could support an APOKYN opportunity?

Licensing opportunities may arise in four areas:

1. Antioxidant or injectable-stability technology.
2. Prefilled syringe, cartridge, or autoinjector platforms.
3. Specialty Parkinson’s distribution and patient-support infrastructure.
4. Manufacturing capacity for sterile, low-volume injectable products.

The most valuable deal structure would combine formulation rights with device rights and commercial access. A formulation-only license may not create a complete product if the licensee lacks a validated delivery system or specialty sales channel.

How strong is the APOKYN patent estate?

The commercial strength of an APOKYN-related patent estate depends on claim breadth, remaining term, Orange Book listing, enforceability, and the ease of designing around the claims.

A strong estate would include:

• A broad but technically supported stabilized composition claim.
• Claims covering sulfite-free and oxygen-controlled embodiments.
• Device claims covering the commercial presentation.
• In-use and container-closure claims.
• Manufacturing claims that are difficult to avoid.
• Method-of-use claims aligned with the marketed label.

A weak estate would rely on a narrow pH range, a single excipient concentration, or a device configuration that can be bypassed by a conventional vial product. Patent strength should be assessed together with regulatory switching costs and prescriber adoption, not from claim count alone.

What generic launch scenarios exist for APOKYN?

Three launch scenarios are commercially plausible:

Conventional generic injection

This product would compete primarily on price and supply reliability. It would have the lowest differentiation but could enter through an ANDA if it satisfies sameness requirements.

Sulfite-free 505(b)(2) product

This product could command a premium if it demonstrates a meaningful safety or tolerability advantage. The regulatory program would be more complex, but the product could avoid direct price competition.

Device-led rescue product

A pen or autoinjector could compete on ease of use and dosing reliability. The commercial outcome would depend on reimbursement, training, device reliability, and whether the product materially reduces caregiver burden.

Key Takeaways

• APOKYN uses sodium metabisulfite as an antioxidant in an acidic aqueous apomorphine injection.
• The leading excipient opportunity is a sulfite-free formulation with equivalent or improved stability.
• Prefilled syringes, cartridges, and autoinjectors could create stronger commercial differentiation than a minor excipient change.
• Apomorphine’s oxidation sensitivity makes oxygen exposure, light, metal contamination, and container compatibility central development issues.
• Original FDA exclusivity has expired; current market protection depends on patents, device rights, manufacturing know-how, and market access.
• A conventional generic would face a lower technical barrier but weaker differentiation.
• A 505(b)(2) formulation or device product could support premium positioning if it reduces sulfite exposure, injection volume, preparation steps, or dosing errors.
• Patent value will depend on claim breadth and design-around difficulty, not the number of formulation or device filings.

FAQs

Can sodium metabisulfite be removed from APOKYN?

Yes, but removal requires a replacement oxidation-control strategy. The alternative must maintain apomorphine stability, sterility, impurity control, container compatibility, and shelf life.

Could a sulfite-free APOKYN qualify for FDA approval without a full clinical program?

Potentially. A 505(b)(2) application could rely partly on the reference product’s safety and efficacy findings, but the applicant would need to justify the new formulation and generate data for material differences.

Is a higher-strength apomorphine injection commercially attractive?

It could be attractive because it may reduce injection volume and enable a compact delivery device. The main risks are local tolerability, precipitation, dose accuracy, viscosity, and stability.

Does an autoinjector create separate patent value?

Yes. Claims may cover the device, cartridge, dose-setting mechanism, formulation-device combination, and delivery method. Device patents can provide protection even when the active ingredient and basic injection formulation are no longer exclusive.

What is the largest commercial risk for an APOKYN generic?

The largest risk is limited market scale combined with specialty commercialization requirements. A generic must secure sterile injectable capacity, reliable distribution, prescriber access, patient training, and reimbursement while competing against established rescue-treatment alternatives.

References

1. U.S. Food and Drug Administration. (2024). APOKYN (apomorphine hydrochloride injection) prescribing information. FDA.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
3. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2). FDA.
4. U.S. Food and Drug Administration. (2022). Container closure systems for packaging human drugs and biologics. FDA.
5. U.S. Food and Drug Administration. (2016). Human factors studies and related clinical study considerations in combination product design and development. FDA.